Phase I Holdings

Celerion is a leading global contract research organization (CRO) specializing in early-stage clinical development and bioanalytical services. The company was established in 2010 when Phase I Holdings, LLC, an investment vehicle of MTS Health Investors, acquired the early-stage development assets of MDS Pharma Services. Celerion provides a comprehensive suite of services for Phase I and Phase IIa clinical trials, including clinical pharmacology, study design, and data management. The company operates large-scale clinical facilities in North America and Europe, supported by advanced bioanalytical laboratories that provide critical data for drug development programs. Celerion serves a diverse global client base, ranging from emerging biotechnology firms to large multinational pharmaceutical corporations. In 2021, the company was acquired by a consortium led by Blackstone and CPP Investments to support its continued growth and expansion of services.